Drugs / LCAR-M61SQ
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| — | NCT06888752 | Mar 2025 → Jun 2030 expected | refractory plasma cell neoplasm | First Affiliated Hospital of Wenzhou Medical University | Not yet recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LCAR-M61SQ | “All subjects who meet the eligibility criteria will receive intravenous injection of LCAR-M61SQ cell injection.” NCT06888752 ↗ |
| Modality | Cell therapy | “LCAR-M61SQ cells intravenous infusion” NCT06888752 ↗ |
| Route | Intravenous | “LCAR-M61SQ cells intravenous infusion” NCT06888752 ↗ |